OCT 10, 2017 09:00 AM PDT
WEBINAR: Automated single cell dissociation of primary tumors and patient-derived xenografts
SPONSORED BY: Miltenyi Biotec
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
4 12 2657

Speakers:
  • Assistant Laboratory Member, Memorial Sloan Kettering Cancer Center Medicine
    Biography
      My lab focuses on development of new patient derived xenograft models and experimental lung cancer therapeutics. During my career I have developed a wide range of skills in both laboratory based and computational research. My hybrid skill set positions me well to operate at the interface between the world of the wet lab and that of the high-performance computing cluster. My research has focused on the genetic and epigenetic landscapes of small cell lung cancer, therapeutic targeting of the DLL3, and development of oncolytic viral therapies. In addition to my primary research focus, I established and currently oversee an active program in patient-derived xenograft development and characterization. Through this program I have developed a series of best practices for genetic characterization of human xenografts grown in mice and biomarker validation in PDX.

    Abstract:

    DATE: October 10, 2017
    TIME: 9:00AM PDT

    Patient-derived xenografts (PDX) are increasingly being used in biomedical research for therapeutic analysis in mice. Unlike traditional cell line xenografts, which are established from suspensions of cultured cells, PDX are maintained entirely in vivo. While exclusive in vivo maintenance is the primary advantage of PDX as a model for cancer, the practice introduces unique challenges and potential pitfalls to working with PDX as a model for cancer. Perhaps the most significant challenge to working with PDX is the need to disaggregate solid tumors prior to their use in downstream applications such as flow cytometry, immunomagnetic enrichment, single-cell sequencing or the establishment of cohorts for therapeutic trials. This webinar will discuss our experience with automated single cell dissociation of primary tumors and patient-derived xenografts as well as compatibility with downstream applications.

     

    Learning Objectives:

    • Advantages and challenges associate with using PDX models for cancer research
    • Solid tumor dissociation methods compatible for downstream single-cell applications, such as flow cytometry, immunomagnetic enrichment and single-cell sequencing

    Show Resources
    Loading Comments...